Keryx Biopharmaceuticals Receives Positive Scientific Advice from the European ... - PR Newswire (press release) PDF Print
PR Newswire (press release)
Zerenex (ferric citrate), a ferric iron-based phosphate binder, is currently in Phase 3 clinical development in the United States for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.